The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.
about
Goblet cell carcinoids of the appendixSmall bowel neuroendocrine tumors: From pathophysiology to clinical approachCurrent state of knowledge on neuroendocrine small bowel tumours: non-systematic review of the literature based on one caseGoblet cell carcinoids of the appendix: Tumor biology, mutations and management strategiesThe somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells[Surgical strategies for accidental detection of appendix carcinoids].Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States.Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs.Pancreastatin predicts survival in neuroendocrine tumors.Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review.Biochemical prognostic indicators for pancreatic neuroendocrine tumors and small bowel neuroendocrine tumorsEvaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumorsGoblet cell carcinoids: characteristics of a Danish cohort of 83 patients.Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.Management of early gastrointestinal neuroendocrine neoplasms.Silencing of UCHL1 by CpG promoter hyper-methylation is associated with metastatic gastroenteropancreatic well-differentiated neuroendocrine (carcinoid) tumors.A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report.Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review.Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies.Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumorsA multimodal approach to the management of neuroendocrine tumour liver metastasesAntitumor effects of somatostatin analogs in neuroendocrine tumors.Molecular pathology of pancreatic neuroendocrine tumors.Management of Appendix Cancer.Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study.Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine TumorsLiver-directed surgery of neuroendocrine metastases: What is the optimal strategy?Giant pancreatic insulinoma. The bigger the worse? Report of two cases and literature reviewAppendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and OutcomeTargeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learnedProposal for a standardized pathology report of gastroenteropancreatic neuroendocrine tumors: prognostic significance of pathological parametersUpdate on management of midgut neuroendocrine tumors.Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors.Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors.Postoperative surveillance of small appendiceal carcinoid tumors.A case of very well-differentiated adenocarcinoma with carcinoid tumor in the ascending colon.Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.
P2860
Q21284834-DED87968-EDB1-41C7-A3FC-6087219318E9Q26766650-67443791-00FB-49ED-817D-BE664CFA0F0DQ26865730-175DFF9D-F667-402F-958B-627C3904A84BQ28073184-F3063E22-D2FD-4129-906C-F0B6FEE15AE9Q28484664-185950AE-AC16-4144-B670-EC627CC186BDQ30318424-65D1AC15-628C-40F8-A15B-7E0E8956D6D2Q33601383-8BB1FBF4-2B4B-417D-80D4-15FC56C49330Q33859561-77354DFB-EFDA-4943-9490-554E22A23571Q34016884-407BB28F-05D4-4DC0-B90F-8C96EE014FA3Q34157385-7F20B303-E36D-4F9B-9FA3-9101E6CFE055Q34400151-01921FCF-899F-4808-AE63-367EC85D500DQ34573558-D672AD2C-C3AA-485B-9089-196D516B33D5Q34688938-F16FE564-C1A3-49FC-A05A-0907757109FEQ35074655-21532DFD-1594-42AF-9119-8523313744A7Q35128224-F82A4B45-0D49-419A-80FC-91617911CE82Q35174840-4B92DE70-548F-4777-8248-E96AF51FB630Q35229834-2057905F-8A7E-4269-9A4C-B4E25BB351C4Q35284530-91B20231-7493-4CA1-9959-8D1EED312015Q35371197-24EA7C22-A9EE-441E-B1BA-190899D01951Q35440550-20074F17-5459-4781-90DE-FD901F48AE90Q35675435-D87E499A-1F23-4A67-BFF4-ABD35A9D7186Q35747137-B6973070-1D31-4756-AD3D-14377BC84CD1Q35810562-584880A2-412D-410A-AD71-20A8000B3E3DQ36051476-ADC4213B-0035-4389-932D-8D0A8770E13DQ36162528-AB1EDBF1-B566-49BF-8FD0-EC25B10F955AQ36304763-54CFAAF3-60A1-4C9A-A875-A053C7078287Q36306654-61889940-FD68-4374-9910-A5410B1CEBEDQ36330126-45FC8CCC-4D26-4DC9-94F6-803B87C98D2CQ36395882-59AD34A0-2833-41FB-8C99-45D72C71EBF9Q36705897-F6F21FAD-C4C7-41C4-BB77-F340F414D4BEQ36832157-07B4A078-6F64-4C6A-BE47-A4EA35D02D06Q36871673-7AD66790-94D7-48D9-A4E6-6ECA77AE68DDQ36983412-54695F02-997E-476C-A2FA-85F617791BFFQ37025143-5509E9B8-2DFD-442E-BC78-2540F82AC16CQ37080296-D46737DA-248B-458A-84C2-7B3B36BF1653Q37085554-1ABB07F5-C8CC-46D8-9373-DE807D7C9AC3Q37531108-19F18C57-8BFD-40AB-A1F8-87E9BFDBCDE5Q37619376-689433C4-3482-45F7-A05A-C4E24601ACCCQ37670892-C6D3E2A6-7E10-492E-8282-E21A812F7BFBQ37677552-EE7EF4AC-B28D-4792-91BA-05FF8C5987AD
P2860
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The NANETS consensus guideline ...... m, Ileum, Appendix, and Cecum.
@en
The NANETS consensus guideline ...... m, Ileum, Appendix, and Cecum.
@nl
type
label
The NANETS consensus guideline ...... m, Ileum, Appendix, and Cecum.
@en
The NANETS consensus guideline ...... m, Ileum, Appendix, and Cecum.
@nl
prefLabel
The NANETS consensus guideline ...... m, Ileum, Appendix, and Cecum.
@en
The NANETS consensus guideline ...... m, Ileum, Appendix, and Cecum.
@nl
P2093
P1433
P1476
The NANETS consensus guideline ...... m, Ileum, Appendix, and Cecum.
@en
P2093
Charles Nutting
David S Klimstra
Eugene A Woltering
J Philip Boudreaux
James C Yao
Manal M Hassan
Martyn E Caplin
North American Neuroendocrine Tumor Society (NANETS)
Robert T Jensen
Stanley J Goldsmith
P304
P356
10.1097/MPA.0B013E3181EBB2A5
P577
2010-08-01T00:00:00Z